Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 40Neoplasm Metastasis 7Neoplasms 6Breast Neoplasms, Male 6Unspecified Adult Solid Tumor, Protocol Specific 3Ovarian Neoplasms 3Brain Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Solid Tumors 2Lung Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumors 2Waldenstrom Macroglobulinemia 1Thyroid Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Oligodendroglioma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Trastuzumab 1Paclitaxel 1MM-111 1Lapatinib 1Docetaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × HER-2 Gene Amplification × Lapatinib × Clear all
NCT01304784 2015-12-16

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Merrimack Pharmaceuticals

Phase 1 Completed
100 enrolled

HER-2 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡